Disclosed herein is the use of a cyclodextrin and/or a functional cyclodextrin derivative selected from the group consisting of á-cyclodextrin, â-cyclodextrin, ã-cyclodextrin, (2-hydroxypropyl)- â-cyclodextrin, and (sulfobutylether-7 â-cyclodextrin and mixtures thereof to increase the stability of an ultrashort-effective â-adrenoreceptor antagonist selected from the group consisting of esmolol, landiolol and flestolol or a pharmaceutically active salt thereof in a storage-stable aqueous solution suitable of parenteral administration. Also disclosed is a pharmaceutical composition for the parenteral administration of an ultrashort-effective â-adrenoreceptor antagonist in the form of a storage-stable solution essentially consisting of: · an ultrashort-effective â-adrenoreceptor antagonist selected from the group consisting of esmolol, landiolol and flestolol or a pharmaceutically active salt thereof · water； and · a cyclodextrin and/or a functional cyclodextrin derivative selected from the group consisting of á-cyclodextrin, â-cyclodextrin, ã-cyclodextrin, (2-hydroxypropyl)- â-cyclodextrin, and (sulfobutylether-7 â-cyclodextrin and mixtures thereof.
